LifeMD (LFMDP) Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 Revenue: $46.9 million, up 4% year-over-year.

Active Subscribers: Nearly 323,000, a 16% increase from the previous year.

Gross Margin: 87.1%, an increase of 570 basis points year-over-year.

GAAP Net Income: $19 million ($0.41 per share), which includes a one-time gain from the sale of WorkSimpli. Excluding this, the net loss from continuing operations was $1.9 million ($0.04 per share).

Adjusted EBITDA: $4.8 million, up from $1.1 million in Q4 2024.

Full Year Revenue: $194.1 million, a 25% increase from 2024.

Cash Position: $36.8 million with no debt.

2Strategic Updates and Business Highlights

Patient Acquisition: LifeMD is onboarding approximately 1,200 new patients daily, with a significant focus on weight management, seeing record sign-ups of nearly 700 per day.

Partnerships: Launched oral Wegovy in collaboration with Novo Nordisk, enhancing access to weight management therapies.

Women's Health Initiative: Acquired Optimal Human Health to bolster women's health offerings, focusing on menopause and hormonal health, with significant investments in marketing and advisory talent.

Pharmacy Operations: The in-house pharmacy is now licensed in all 50 states, processing about 20,000 prescriptions monthly, contributing to margin expansion.

AI Integration: Plans to launch an AI clinical decision support tool to enhance patient care and operational efficiency.

3Forward Guidance and Outlook

Q1 2026 Revenue Guidance: Expected to be between $48 million and $49 million, with an adjusted EBITDA loss projected between $4 million and $5 million due to increased marketing investments.

Full Year 2026 Revenue Guidance: Anticipated between $220 million and $230 million, with adjusted EBITDA projected between $12 million and $17 million.

Long-term Growth: Expected annualized revenue run rate to exceed $250 million and adjusted EBITDA to exceed $25 million by Q4 2026.

4Bad News, Challenges, or Points of Concern

Net Loss from Continuing Operations: Despite a strong revenue performance, the company reported a net loss when excluding one-time gains.

Women's Health Launch: While demand is strong, the women's health segment is not expected to be EBITDA positive in its first year, potentially delaying profitability contributions.

Competitive Pressures: New entrants like Amazon and Lilly in the weight management space could pose risks to market share and patient acquisition.

5Notable Q&A Insights

Demand for Wegovy: Strong demand for the oral Wegovy pill has significantly increased new patient acquisition, with approximately 80% of new sign-ups opting for branded therapy.

Patient Acquisition Costs (CAC): CAC has declined by 4% sequentially, despite increased marketing spend, indicating improved efficiency.

Insurance Coverage: The expansion of insurance coverage is expected to enhance patient retention and lifetime value, although the long-term impact is still being evaluated.

Market Differentiation: LifeMD emphasizes its unique position with a dedicated provider group and a comprehensive care platform compared to competitors like Amazon. Overall, LifeMD demonstrated solid financial performance and strategic initiatives aimed at long-term growth, while also facing challenges related to competition and the early-stage performance of new offerings.